Board of directors


Martin Nicklasson
Chairman of the Board
Chairman of the Remuneration and
Compensation Committee
Chairman of the Nomination Committee
Elected to the Board in 2015 and regarded as an independent board member.


Certified pharmacist.
Ph.D. in Pharmaceutical Technology from the University of Uppsala, where he is an Associate Professor in the Department of Pharmaceutics.

Martin Nicklasson has served as President of Nicklasson Life Science AB since 2011. He has also held various Executive Vice President positions at AstraZeneca plc and has served as President and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB (publ). Prior to this, he held a number of leadership positions at Astra and Kabi Pharmacia. Martin Nicklasson is chairman of the board of Orexo AB and Kymab Group Ltd.. He serves as a board member of Basilea Pharmaceutica Ltd. andBioCrine AB, . He previously served as a board member of Scandinavian Life science invest AB, Denator AB, Pozen Inc., Oasmia AB, Farma Investment AS, PledPharma AB, BioInvent International AB, Premier Research Group Ltd. and EffRx Pharmaceuticals SA within the past five years.


Rosemary Crane
Vice Chairman of the Board

Elected to the Board in 2015 and
regarded as an independent board member.

BA in Communication from the State University of New York and MBA from Kent State University.

Rosemary Crane has been CEO of Mela Sciences and Epocrates, and has held a
number of leading positions at Johnson & Johnson and BMS. She has a background in marketing and a knowledge base in diabetes and cardiovascular disease, among others. Rosemary Crane is a member of the boards of Teva
Pharmaceutical Industries Ltd. and Unilife (a medical technology company).


Catherine Moukheibir
Board member

Chairman of the Audit Committee
Elected to the Board in 2015 and regarded as an independent board member.

MBA from Yale University.

After a career in strategy consulting and investment banking in Boston and
London, Catherine Moukheibir has held senior management positions in
several European biotech companies. Her particular experience lies in aligning
corporate and financial strategy at various stages of a biotech’s development.

Catherine Moukheibir is Chairman of the Board of MedDay Pharmaceuticals S.A.
and a board member of Ablynx S.A. and Cerenis Therapeutics Holding S.A. She is
also a member of the Advisory Board at Imperial College Business School, UK.


Alain Munoz
Board member

Elected to the Board in 2005 (resigned in 2006, was re-elected in 2007) and regarded as an independent board member.

MD in Cardiology and Anaesthesiology,
head of clinical department of cardiology
at the University Hospital of Montpellier. He has numerous publications and
has been a member of the scientific committee of the French Drug Agency.

Alain Munoz is CEO and founder of Amistad Pharma S.A.S. and Science, Business and Management SARL (France), and has over 20 years' experience in the pharmaceutical industry at senior management level. He served as SVP for International development within the Sanofi Group and as SVP for the Pharmaceutical division in Fournier Laboratories.

Alain Munoz is Chairman of the Board of Hybrigenics, a board member of Valneva
SE and adviser to Kurma Biofund.


Michael J. Owen
Board member
Elected to the Board in 2012 and regarded as an independent board member.

Ph.D. in Biochemistry from Cambridge University and BA in Biochemistry from Oxford University.

Michael J. Owen is a co-founder and former CSO of Kymab Ltd. Before joining
Kymab, he held several leading positions at GlaxoSmithKline, latterly as SVP and
head of biopharmaceuticals research. Prior to joining GSK in 2001, he headed the
Lymphocyte Molecular Biology group at the Imperial Cancer Research Fund. He has more than 20 years' research experience with a focus on the immune system. He has more than 150 publications, and is a member of the European Molecular
Biology Organization and Fellow of the Academy of Medical Sciences.

Michael J. Owen is board member of Blink Biomedical SAS, Ossianix, Inc., Avacta
Group plc, ReNeuron Group. Plc and GammaDelta Therapeutics. He is also
adviser to Kymab Ltd and CRT Pioneer Fund LP.


Jens Peter Stenvang
Employee-elected board member
Elected to the Board in 2014.

Laboratory Technician (Biology). Jens Peter
Stenvang is a senior application specialist and has worked on cancer and diabetes research at leading universities, including UC Berkeley, California. Before joining Zealand in October 2010, Jens Peter Stenvang worked for Dako and Beckman Coulter in global flow cytometry support.


Hanne Heidenheim Bak 
Employee-elected board member
Elected to the Board in 2012-2014 and re-elected in 2016.

M.Sc. (Pharm) from the Danish University of Pharmaceutical Sciences. Hanne H. Bak is Senior Project Director and R&D Operations Manager
and has worked as Project Leader of late-phase development programs at H. Lundbeck A/S, followed by a position as Executive Director at the Lundbeck Institute.


Rasmus Just
Employee-elected board member

Elected to the Board in 2016.

Ph.D. in Molecular Pharmacology from the
University of Copenhagen and Executive MBA from AVT Business School in Copenhagen. Rasmus Just is Director of Business Development and Innovation Sourcing and has previously held positions as Principal Scientist, Head of Cardiometabolic Innovation and been responsible for the collaboration
with Boehringer Ingelheim GmbH.